- Record: found
- Abstract: found
- Article: found
HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex†
brief-report
Keita Yamana
a ,
Riku Kawasaki
a
,
,
Kousuke Kondo
a ,
Hidetoshi Hirano
a ,
Shogo Kawamura
a ,
Yu Sanada
b ,
Kaori Bando
c ,
Anri Tabata
c ,
Hideki Azuma
c ,
Takushi Takata
b ,
Yoshinori Sakurai
b ,
Hiroki Tanaka
b ,
Tomoki Kodama
d ,
Seiji Kawamoto
d ,
Takeshi Nagasaki
c ,
Atsushi Ikeda
a
,
1 June 2023
25 July 2023
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The development of boron agents with integrated functionality, including biocompatibility, high boron content, and cancer cell targeting, is desired to exploit the therapeutic efficacy of boron neutron capture therapy (BNCT). Here, we report the therapeutic efficacy of BNCT using a HER-2-targeted antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. The anticancer effect of BNCT using our system was 30-fold that of the clinically available boron agent l-BPA/fructose complex.
Abstract
HER-2 targeted boron nitride nanotube was developed as a boron agent for boron neutron capture therapy.
